Form 4: Immunovant's Chief Medical Officer Sells Shares to Cover Tax Obligations
SEC Form 4
William L. Macias, Chief Medical Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On January 15, 2025, William L. Macias, the Chief Medical Officer of Immunovant, Inc., sold shares of the company's common stock.
- The sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- A total of 1,883 shares were sold at a weighted average price of $23.81, with individual transactions ranging from $23.13 to $24.07 per share.
- Additionally, 94 shares were sold at a weighted average price of $24.19, with individual transactions ranging from $24.13 to $24.21 per share.
- Another 387 shares were sold at a weighted average price of $23.81, with individual transactions ranging from $23.13 to $24.07 per share.
- Finally, 19 shares were sold at a weighted average price of $24.19, with individual transactions ranging from $24.13 to $24.21 per share.
- These sales were mandated by Immunovant's policy requiring tax obligations to be funded through 'sell to cover' transactions and do not represent discretionary sales by Mr. Macias.
- Following these transactions, Mr. Macias beneficially owns 359,408 shares of Immunovant common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a routine transaction (sell to cover taxes). It doesn't inherently convey positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- The sale of shares by an insider could be perceived negatively by some shareholders, although the 'sell to cover' explanation mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| June 11, 2021 | Grant date of 18,674 restricted stock units (RSUs). |
| April 12, 2023 | Grant date of 87,664 restricted stock units (RSUs). |
| January 12, 2025 | 5,479 RSUs vested from the April 12, 2023 grant. |
| January 13, 2025 | 1,167 RSUs vested from the June 11, 2021 grant. |
| January 15, 2025 | Date of share sales to cover tax obligations. |
| January 17, 2025 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.